Intriguingly, the addition of KC7F2 significantly strengthened the anticancer effects of MTX (Fig. 5A) and CIS (Fig. 5B), although no TGF-β was used to treat the tumor-bearing mice. This evidence concerns the gene TGFB1 and in situ carcinoma.